Financial statements are reported in EUR and shown here converted to USD at today's exchange rate.
IPHA — Innate Pharma S.A.
$1.38
$-0.11 (-7.38%)
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Market Cap
$154.15M
Forward P/E
-3.0x
52-Week Range
N/A
IPHA Price History
Revenue vs. Net Income
$9.9M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$38.5M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-186.9%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.7x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
26.1%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+10.5%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
